Welcome to our dedicated page for 180 Life Sciences SEC filings (Ticker: ATNFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
180 Life Sciences Corp. filings document the issuer’s securities, capital structure, governance actions and corporate-status changes, including its completed name change to ETHZilla Corporation. Recent Form 8-K reports address Nasdaq-listed common stock and warrants, ticker changes to ETHZ and ETHZW, warrant exercises, unregistered equity issuances, private placements, convertible notes and Regulation FD disclosures.
The filing record also includes material definitive agreements, amendments to prior event reports, shareholder-rights and governance matters, and disclosures related to the company’s ETH accumulation strategy. Earlier public-company records provide context for the issuer’s history as a clinical-stage biotechnology company focused on inflammatory diseases, fibrosis and pain.
180 Life Sciences Corp. (NASDAQ: ATNF/ATNFW) filed an 8-K on 12 June 2025 detailing several board and compensation-related actions.
Director resignation & release. Jay Goodman resigned from the Board effective 13 June 2025. Under a Release Agreement the company paid (a) $7,583.33 in accrued fees, (b) $36,750 representing future board fees through 31 Dec 2025, and (c) an additional $54,000. Goodman issued a broad release, accepted standard restrictive covenants, and forfeited 65,000 unvested shares, which the company has cancelled.
Adoption of the 2025 Option Incentive Plan. On 17 June 2025 the Board adopted the 2025 Plan, reserving 1,000,000 shares of common stock for employee, director and consultant stock options. Consistent with Nasdaq rules, options cannot be exercised until shareholder approval is obtained within 12 months; failure to secure approval will unwind the plan and cancel any awards.
Executive compensation adjustments. • 160,000 previously granted restricted shares to CEO Blair Jordan were fully vested as of 17 June 2025 (previously scheduled to vest during 2026). • Option grants: Jordan – 410,000 shares; CAO Eric R. Van Lent – 25,000 shares; 10-year term; exercise price $0.9290; 50% vests at six months and the remaining 50% at 12 months. • Restricted stock grants: Jordan – 179,646 shares; Van Lent – 8,763 shares, with the same vesting schedule, issued under the 2022 Omnibus Incentive Plan.
Amended CEO consulting agreement. Effective 1 June 2025, the company extended Jordan’s consulting arrangement through 31 Dec 2027 at an unchanged base fee of $240,000 per year, rising to $350,000 if a ≥$100 million transaction closes. The bonus structure was modified to guarantee a minimum 50% annual bonus opportunity (previously discretionary up to 100%).
Investor take-aways. The filing signals ongoing effort to retain and incentivize key executives but introduces potential dilution from up to 1 million new option shares plus accelerated/ new equity awards. Cash outflows tied to Goodman’s departure are modest. No disagreements with the resigning director were disclosed, mitigating governance concerns, yet the board must fill the vacancy in due course. Material financial metrics were not provided, so immediate earnings impact appears limited, but future share count and compensation expense could rise if all equity awards vest and options are exercised.